{"filings":[{"id":2106365,"accession_number":"0001628280-26-054353","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2026-08-06T20:19:48+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical Q2 net sales $789.6M (+5.9%); non-GAAP EPS $1.34 (+55.8%), raises FY EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide net sales $789.6M, +5.9% YoY; US +3.0%, International +18.0% as-reported.","GAAP diluted EPS $1.10 (-26.2% YoY) due to prior-year bargain purchase gain; non-GAAP diluted EPS $1.34 (+55.8%).","US Spine grew 7% YoY; International Spine grew 14% as-reported (12% constant currency).","Adjusted gross margin expanded 200 bps YoY; record Q2 non-GAAP net income and EPS.","FY2026 revenue guidance reaffirmed $3.18B-$3.22B; non-GAAP EPS guidance raised to $4.95-$5.05 from $4.70-$4.80."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":861160,"accession_number":"0001628280-26-040784","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2026-06-04T20:11:31+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Globus Medical shareholders approve 1M share increase to equity plan, re-elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2021 Equity Incentive Plan, increasing authorized shares by 1,000,000 to 12,000,000.","Keith Pfeil and Robert A. Douglas re-elected as Class II directors with substantial majority support.","Deloitte & Touche LLP ratified as independent auditor for fiscal year ending December 31, 2026.","Non-binding advisory vote on 2025 executive compensation passed with 316M for vs. 5.2M against.","No other matters were submitted to stockholders at the June 3, 2026 Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91790,"accession_number":"0001628280-26-032164","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical Q1 2026: Net sales $759.9M (+27% YoY); raises FY non-GAAP EPS guidance to $4.70-$4.80","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $0.90 (+66.6% YoY); non-GAAP diluted EPS $1.12 (+64.7% YoY).","Worldwide net sales $759.9M, up 27% as-reported; base business (ex-Nevro) up 13.2%.","FY2026 revenue guidance reaffirmed at $3.18B–$3.22B; non-GAAP EPS guidance raised to $4.70–$4.80 from $4.40–$4.50.","U.S. net sales +25% YoY; international +35.6% as-reported (+27.8% constant currency).","Operating margin expanded on manufacturing initiatives and operating leverage."],"consensus_eps_estimate":null,"consensus_eps_actual":0.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":759854000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102128,"accession_number":"0001628280-26-020612","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Director John A. DeFord resigns from Globus Medical Board effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John A. DeFord, Ph.D., notified the Board of his resignation on March 23, 2026, effective immediately.","DeFord stated his decision was not a result of any disagreement with the company.","He will not seek re-election at the Annual Meeting of Stockholders scheduled for June 3, 2026.","Chairman David C. Paul thanked DeFord for his contributions, especially during the NuVasive merger.","DeFord served on the Nominating and Governance Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102127,"accession_number":"0001628280-26-011124","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical Q4 revenue $826.4M (+25.7% YoY); EPS $1.03 GAAP / $1.28 non-GAAP","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 worldwide net sales $826.4M, up 25.7% YoY; base business ex-Nevro up 10.6%.","GAAP diluted EPS $1.03 (vs $0.19); non-GAAP diluted EPS $1.28 (vs $0.84), up 52.1%.","Full year 2025 revenue $2,938.9M (+16.7%); GAAP EPS $3.92; non-GAAP EPS $3.98.","2026 guidance: revenue $3.18-3.22B; non-GAAP EPS raised to $4.40-4.50 from $4.30-4.40.","US Spine revenue grew 10% in Q4; Enabling Technologies grew 19% over prior-year quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":3.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":2938931000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102126,"accession_number":"0001628280-26-001189","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical reports record Q4 sales $823M (+25% YoY); FY2026 guidance $3.18-3.22B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2025 sales ~$823.2M, +25.2% YoY; full year sales ~$2.936B, +16.5% YoY.","Base business (ex-Nevro) Q4 revenue $723.3M, +10.0% YoY, led by US Spine.","Enabling Technologies delivered best quarterly revenue performance to date.","FY2026 revenue guidance $3.18B-$3.22B; non-GAAP EPS guidance $4.30-$4.40.","Final Q4/FY2025 results expected on February 24, 2026 after market close."],"consensus_eps_estimate":null,"consensus_eps_actual":3.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":2938931000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118445,"accession_number":"0001237831-25-000029","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical Q3 revenue $769M (+23% YoY); raises FY2025 EPS guidance to $3.75-$3.85","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $769.0M, +22.9% YoY; base business (ex-Nevro) $669.8M (+7.0%); Nevro contributed $99.3M.","GAAP diluted EPS $0.88, up 134% YoY; non-GAAP diluted EPS $1.18, up 42.6% YoY.","FY2025 revenue guidance raised to $2.86-$2.90B; non-GAAP EPS raised to $3.75-$3.85 (prev $3.00-$3.30).","Record non-GAAP free cash flow of $213.9M in Q3; share repurchases of $40M in Q3, total $255.5M YTD.","Nevro acquisition now expected to be accretive to earnings in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":2.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":2112511000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134877,"accession_number":"0001562762-25-000198","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical Q2 net sales $745.3M (+18.4%); GAAP EPS $1.49, non-GAAP $0.86","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $745.3M, up 18.4% YoY (17.6% constant currency); US Spine grew 5.7% as-reported.","GAAP net income $202.8M ($1.49 diluted EPS) vs $31.7M ($0.23) a year ago; includes $110.6M bargain purchase gain.","Non-GAAP diluted EPS $0.86 vs $0.75 (+14.1%); record quarterly non-GAAP EPS.","Full-year 2025 guidance reaffirmed: revenue $2.80-2.90B; non-GAAP EPS $3.00-3.30.","Closed Nevro acquisition; net cash from ops $77.9M, non-GAAP free cash flow $31.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":2.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":1343463000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134876,"accession_number":"0001562762-25-000166","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Globus Medical CEO Scavilla resigns; Pfeil named CEO; preliminary Q2 sales $745.3M (+18% YoY)","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Daniel Scavilla resigned as President and CEO effective July 18, 2025 to pursue another opportunity; no disagreement cited.","Keith Pfeil, formerly COO/CFO, appointed President and CEO effective July 18, 2025; also joins Board.","Kyle Kline appointed CFO effective July 18, 2025; previously SVP of Finance.","Preliminary Q2 2025 sales ~$745.3M, up 18.4% as reported; base business ex-Nevro up 4.8% day-adjusted.","Full-year 2025 guidance reaffirmed: revenue $2.80–$2.90B, non-GAAP EPS $3.00–$3.30."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151836,"accession_number":"0001562762-25-000158","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Globus Medical stockholders approve equity plan amendment, elect directors at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected four directors to three-year terms: Paul, Lemaitre, Norwalk, Rhoads.","Amendment to 2021 Equity Incentive Plan approved: 247M for, 76M against.","Ratified Deloitte & Touche as auditor with 329M votes for.","Advisory vote on executive compensation approved: 315M for, 7.6M against.","Stockholders recommended 1-year frequency for say-on-pay; Board adopts annual vote until 2031."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151835,"accession_number":"0001562762-25-000131","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Globus Medical authorizes $500M share repurchase program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized up to $500M buyback of Class A common stock.","CFO cites disconnect between intrinsic value and market valuation.","Repurchases at management's discretion; no time limit, can be suspended.","Funding from cash reserves; program aligns with capital allocation strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151834,"accession_number":"0001562762-25-000114","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical Q1 revenue down 1.4% to $598.1M; cuts non-GAAP EPS guidance to $3.00-$3.30","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $75.5M; GAAP diluted EPS $0.54 vs ($0.05) a year ago.","Non-GAAP diluted EPS $0.68, up 8.5% YoY; prior guidance $3.10-$3.40 now $3.00-$3.30.","Revenue fell 1.4% as-reported (0.8% constant currency); US up 0.2%, Intl down 7.7% as-reported.","Paid off remaining $450M debt from NuVasive merger; Q1 free cash flow $141.2M.","Company cites softer Enabling Technology deals, supply chain disruption, and timing of intl orders."],"consensus_eps_estimate":null,"consensus_eps_actual":0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":598121000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151833,"accession_number":"0001193125-25-071923","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["2.01","7.01","9.01"],"status":"ready","headline":"Globus Medical completes acquisition of Nevro Corp. for $5.85/share cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Completed acquisition of Nevro on April 3, 2025; each Nevro share received $5.85 in cash.","Nevro stock options and RSUs canceled; RSUs converted to cash equal to Merger Consideration.","Acquisition expands Globus's addressable market opportunity to $2 billion in neuromodulation.","Nevro common stock ceased trading on NYSE as of April 3, 2025.","Globus plans to discuss merger benefits during Q1 2025 earnings call in May."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170698,"accession_number":"0001562762-25-000024","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical Q4 sales $657.3M (+6.6% YoY); guides 2025 with Nevro acquisition impact","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $657.3M (+6.6% as-reported, +6.9% constant currency); GAAP EPS $0.19, non-GAAP EPS $0.84.","Full-year 2024 net sales $2,519.4M (+60.6% YoY); GAAP net income $103.0M; GAAP EPS $0.75, non-GAAP EPS $3.04.","2025 stand-alone guidance: revenue $2.66-2.69B, non-GAAP EPS $3.40-3.50; with Nevro acquisition (close late Q2): revenue $2.80-2.90B, non-GAAP EPS $3.10-3.40.","Q4 non-GAAP adjusted EBITDA $196.9M (30.0% of sales); full-year operating cash flow $520.6M, free cash flow $405.2M.","CEO cites record product launches and integration progress; team executed on strategic objectives to drive value."],"consensus_eps_estimate":null,"consensus_eps_actual":0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":2519355000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170697,"accession_number":"0001193125-25-021848","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Globus Medical to acquire Nevro for $5.85/sh in all-cash deal valued at ~$250M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["All-cash transaction at $5.85/share; 27% premium to 90-day VWAP of $4.61.","Total equity value approx. $250M; expected close by late Q2 2025.","Globus Medical expects Nevro acquisition to be accretive to earnings in second year.","Globus reaffirms standalone 2025 net sales guidance $2.66-$2.69B; combined guidance $2.80-$2.90B.","Preliminary 2024 revenue: Globus $2.52B (+60.6% YoY); Nevro $408-$409M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170696,"accession_number":"0001562762-25-000006","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical prelim Q4 sales $657M (+6.6% YoY), FY24 $2.52B; guides FY25 rev $2.66-2.69B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 preliminary net sales ~$657M, up 6.6% as-reported vs Q4 2023; FY2024 ~$2.52B, up 60.6%.","FY2025 revenue guidance $2.66-2.69B; fully diluted non-GAAP EPS $3.40-$3.50.","CEO highlights record product launches and highest Enabling Technology placements post-NuVasive merger.","Full Q4 and FY2024 results to be reported on February 20, 2025 after market close."],"consensus_eps_estimate":null,"consensus_eps_actual":0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":2519355000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187670,"accession_number":"0001562762-24-000250","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical Q3 net sales $625.7M (+63% YoY), raises FY24 revenue and EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide net sales $625.7M, up 63.1% YoY, driven by NuVasive addition and higher spine/enabling tech sales.","GAAP diluted EPS $0.38 (vs $0.01 in Q3 2023); non-GAAP diluted EPS $0.83 (vs $0.57, +45.2%).","Non-GAAP adjusted EBITDA $193.7M, or 31.0% of net sales.","Raised FY2024 guidance: revenue $2.49-$2.50B; non-GAAP diluted EPS $2.90-$3.00 (includes $0.09 change in treatment of IPR&D).","Net cash from operations $203.7M; non-GAAP free cash flow $161.7M in Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":1862062000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204146,"accession_number":"0001562762-24-000209","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Globus Medical receives FDA warning letter for ExcelsiusGPS complaint procedures","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA warning letter cites non-conformities in complaint handling, trending, risk reconciliation, and MDR reporting for the ExcelsiusGPS robotic system.","Inspection occurred Feb 15–Mar 7, 2024; company says deficiencies in response letters to the Form 483.","No safety concerns with use of the system or manufacturing process were identified.","Company has taken corrective actions and believes issues can be resolved without material financial impact.","Until resolution, additional regulatory action may be taken without further notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204145,"accession_number":"0001562762-24-000195","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical Q2 revenue surges 115.9% to $629.7M; GAAP net income down 45%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $629.7M, up 115.9% as-reported; GAAP net income $31.8M, down 45% YoY.","GAAP diluted EPS $0.23; non-GAAP diluted EPS $0.75, up 20% vs $0.63 prior year.","Non-GAAP adjusted EBITDA $190.4M (30.2% of sales); operating cash flow $54.3M, FCF $26.5M.","Raised FY2024 revenue guidance to $2.47B-$2.49B; non-GAAP EPS $2.80-$2.90.","Growth driven by NuVasive acquisition, spine product volume, enabling technology sales."],"consensus_eps_estimate":null,"consensus_eps_actual":0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":1236357000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220878,"accession_number":"0001562762-24-000163","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Globus Medical shareholders approve amendment to 2021 Equity Incentive Plan","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Plan amendment approved with 244,115,224 votes for, 78,950,353 against; effective June 5, 2024.","Material features described in Proxy Statement filed April 26, 2024, incorporated by reference.","Directors elected: Davidar (263.7M for), Tobin (256.5M), Zarrilli (320.0M), Wolterman (322.5M).","Ratification of Deloitte as auditor (329.3M for) and non-binding say-on-pay approved (315.4M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220877,"accession_number":"0001562762-24-000124","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical Q1 net sales $606.7M (+119% YoY); raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $606.7M, up 119.3% YoY, driven by NuVasive addition and higher spine/enabling tech volumes.","GAAP net loss $7.1M (($0.05) diluted EPS); non-GAAP diluted EPS $0.72, up 36.4% from $0.53.","Non-GAAP adjusted EBITDA $166.6M, or 27.5% of net sales.","FY2024 revenue guidance raised to $2.460-2.485B; non-GAAP EPS guidance raised to $2.75-2.85.","Integration of NuVasive progressing; management cites strong surgeon and sales force retention."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":606666000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240471,"accession_number":"0001562762-24-000030","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical Q4 net sales $616.5M (+124.6% YoY); non-GAAP EPS $0.60; reaffirms FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $616.5M, +124.6% as-reported (+123.8% constant currency); driven by NuVasive merger and organic growth.","GAAP net income $15.0M (diluted EPS $0.11) down 70% YoY due to acquisition costs; non-GAAP diluted EPS $0.60 (+2.1%).","Full year 2023 net sales $1,568.5M (+53.3%); GAAP EPS $1.07; non-GAAP EPS $2.32.","Legacy Globus organic revenue grew 10.8% in Q4 and 12.8% for full year vs prior year.","FY2024 guidance reaffirmed: net sales $2.450B-$2.475B; non-GAAP EPS $2.68-$2.70."],"consensus_eps_estimate":null,"consensus_eps_actual":1.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":1568476000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240470,"accession_number":"0001562762-24-000019","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2024-02-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Globus Medical promotes Keith Pfeil to COO and CFO effective Feb 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Keith Pfeil adds COO role to his CFO responsibilities; effective February 1, 2024.","Base salary raised from $414,690 to $460,000; target bonus increased from $325,000 to $600,000.","Pfeil continues reporting to CEO Dan Scavilla; has been with Globus since August 2019.","Company expects to announce Q4 and full-year 2023 results on February 20, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240469,"accession_number":"0001562762-24-000006","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2024-01-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical reports record Q4 sales $615.5M (+124% YoY); FY2024 guidance $2.45-2.475B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 sales ~$615.5M, up 124.2% as-reported, including NuVasive merger impact.","Full year 2023 sales ~$1.567B, up 53.2% as-reported over prior year.","Legacy Globus Q4 revenue $302.9M (+10.4% YoY); full year $1.152B (+12.7%).","FY2024 revenue guidance $2.450-2.475B; non-GAAP EPS guidance $2.68-$2.70.","Completed NuVasive merger Sept 1, 2023; integration on track with strong sales retention."],"consensus_eps_estimate":null,"consensus_eps_actual":1.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":1568476000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257985,"accession_number":"0001193125-23-278012","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K/A","filed_at":"2023-11-15T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Globus Medical files pro forma financials for NuVasive Merger; combined net income $6M for 9 months","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Pro forma net income for nine months ended Sep 30, 2023: $6.0M ($0.04 diluted EPS) vs Globus standalone $107.8M.","Total purchase price $2.6B; goodwill $924M, intangible assets $1.22B (developed tech, customer relationships).","Pro forma net income for FY2022: $5.2M ($0.04 diluted EPS) vs Globus standalone $190.2M.","NuVasive contributed $827M revenue for Jan–Aug 2023; inventory step-up of $284M added to cost of sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257987,"accession_number":"0001562762-23-000405","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical Q3 revenue $383.6M (+51% YoY); raises FY revenue guidance to $1.55B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $1.0M, diluted EPS $0.01; non-GAAP diluted EPS $0.57 (+14.7% YoY).","NuVasive merger closed Sept 1; combined results from that date drove 51% revenue increase.","Stand-alone Globus Medical net sales $281.2M (+10.7% YoY); U.S. +8.1%, International +25.5%.","Non-GAAP adjusted EBITDA $112.9M (29.4% of sales); free cash flow $29.0M.","FY 2023 revenue guidance raised to $1.55B (from $1.125B); non-GAAP EPS reaffirmed at $2.30."],"consensus_eps_estimate":null,"consensus_eps_actual":0.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":951942000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257986,"accession_number":"0001562762-23-000357","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2023-10-02T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Globus Medical enters $400M credit facility, authorizes $350M stock buyback","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$400M unsecured credit agreement with U.S. Bank as agent; matures Sept 2028.","New $350M stock repurchase program approved by board with no time limit.","About $150.8M remains from prior repurchase programs announced in 2020 and 2022.","Credit facility includes $200M accordion feature, SOFR-based pricing (margin 1.125%-1.625%).","Loan parties include NuVasive as guarantor; leverage ratio covenant applies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275303,"accession_number":"0001193125-23-227191","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2023-09-01T23:59:59+00:00","items":["1.01","2.01","2.03","3.02","5.02","7.01","8.01","9.01"],"status":"ready","headline":"Globus Medical completes merger with NuVasive; expands board, converts notes","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["NuVasive shareholders received 0.75 Globus shares per share; NuVasive stock ceased trading Aug 31.","Globus Board expanded from 8 to 11; added NuVasive directors John DeFord, Leslie Norwalk, Daniel Wolterman.","NuVasive's $450M 0.375% convertible notes now convertible into Globus common at 8.0399 shares/$1,000 principal.","Globus guaranteed NuVasive's note obligations; also amended call/warrant options for Globus stock.","Combined company positioned as leading global musculoskeletal firm; financial benefits to be discussed in Q3 call."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275302,"accession_number":"0001562762-23-000305","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical Q2 net sales $292M (+10.6% YoY); raises FY 2023 guidance to $1.125B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $291.6M, up 10.6% YoY; GAAP net income $57.7M (+5.7%).","GAAP diluted EPS $0.57; non-GAAP diluted EPS $0.63 (+12.3%).","Non-GAAP adjusted EBITDA $96.1M (33.0% of sales).","Raised FY 2023 net sales guidance to $1.125B (from $1.100B); reaffirmed non-GAAP EPS $2.30.","Launched REFLECT Scoliosis Correction System and MARVEL Growing Rod System."],"consensus_eps_estimate":null,"consensus_eps_actual":1.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":568303000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292764,"accession_number":"0001562762-23-000269","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2023-06-08T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Globus Medical stockholders elect directors, approve equity plan amendment, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Daniel T. Scavilla elected with 249.4M votes for, 34.2M withheld; Robert A. Douglas with 281.5M for.","Amendment to 2021 Equity Incentive Plan approved: 229.9M for, 53.7M against, 58.7K abstain.","Deloitte & Touche LLP ratified as auditor for FY2023: 289.5M for, 144K against.","Non-binding advisory vote on executive compensation approved: 278.8M for, 4.9M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292763,"accession_number":"0001562762-23-000208","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical Q1 net sales up 20% to $276.7M; non-GAAP EPS $0.53","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide net sales $276.7M, up 20% YoY (21% constant currency); GAAP net income $49.1M.","GAAP diluted EPS $0.48; non-GAAP diluted EPS $0.53, up 24.7% YoY.","U.S. Spine sales up 14%; Enabling Technologies grew 91% to $25M.","Full-year 2023 guidance reaffirmed: net sales $1.1B, non-GAAP diluted EPS $2.30.","Pending merger with NuVasive received shareholder approvals from both companies."],"consensus_eps_estimate":null,"consensus_eps_actual":0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":276688000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292762,"accession_number":"0001193125-23-134571","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Globus Medical, NuVasive get FTC second request for merger; Q3 2023 close expected","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FTC issued Second Request on May 3, 2023, extending HSR waiting period for the merger.","Both companies received requisite stockholder approvals at April 27, 2023 meetings.","Merger expected to close in Q3 2023, subject to HSR clearance and other conditions.","Globus and NuVasive are cooperating with FTC to satisfy the Second Request."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292761,"accession_number":"0001193125-23-123358","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2023-04-28T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Globus Medical shareholders approve share issuance for NuVasive merger; 99.92% vote in favor","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["99.92% of votes cast approved share issuance; 99.66% of Class A and 100% of Class B voted for.","Exchange ratio: 0.75 Globus Class A shares for each NuVasive share; NuVasive holders to own ~28% of combined co.","Combined company will have over 5,000 employees focused on musculoskeletal solutions and enabling technologies.","Merger expected to close after regulatory clearance and satisfaction of other customary conditions.","Globus Medical to report Q1 2023 earnings on May 4, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292760,"accession_number":"0001193125-23-103804","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2023-04-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Globus Medical and NuVasive disclose supplemental proxy info to settle merger lawsuits","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Five shareholder complaints filed in March-April 2023 in NY, DE, and Colorado courts alleging incomplete/misleading proxy statement for the merger.","NuVasive and Globus Medical deny merit but are making supplemental disclosures to avoid risk of delaying the merger.","Supplemental disclosures add details: no acquisition proposals received during Window Shop Period (ended March 10, 2023).","Supplemental disclosures also provide additional details on Goldman Sachs and BofA financial analyses, including net debt adjustments and discount rate ranges.","Defendants are not admitting legal necessity or materiality of the supplemental disclosures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292759,"accession_number":"0001193125-23-089754","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2023-04-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Globus Medical withdraws, refiles HSR filing for NuVasive acquisition; waiting period ends May 3, 2023","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Voluntarily withdrew HSR filing on March 31, 2023 and refiled on April 3, 2023 to give FTC additional review time.","New 30-day HSR waiting period expires at 11:59 pm ET on May 3, 2023, unless extended or terminated early.","Companies reaffirm expectation that the merger will close in middle of 2023, subject to conditions including stockholder approvals.","Special stockholder meetings for both Globus and NuVasive set for April 27, 2023 to vote on the proposed transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313416,"accession_number":"0001562762-23-000046","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2023-02-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical Q4 net sales $274.5M (+9.8% YoY); full year exceeds $1B; guides 2023 sales $1.1B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP diluted EPS $0.49, non-GAAP diluted EPS $0.59; net income $50.1M (+231% YoY).","Full year 2022 net sales $1,022.8M (+6.8% YoY); GAAP diluted EPS $1.85, non-GAAP $2.06.","Non-GAAP adjusted EBITDA Q4 $90.2M (32.8% of sales); full year $339.2M (33.2%).","2023 guidance: net sales ~$1.1B, non-GAAP diluted EPS $2.30.","Company remains debt-free; net cash from ops $178.5M, free cash flow $104.4M for full year."],"consensus_eps_estimate":null,"consensus_eps_actual":1.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":1022843000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313415,"accession_number":"0001193125-23-030375","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2023-02-09T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Globus Medical to acquire NuVasive in all-stock merger; each NuVasive share gets 0.75 GMED share","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Each NuVasive share converted into 0.75 Globus Medical Class A common shares; no cash consideration except fractional shares.","Expected close by Oct 8, 2023, extendable to Feb 8, 2024; subject to HSR, shareholder approvals, and other conditions.","Termination fees: NuVasive pays $120M (reduced to $75M in Specified Period); Globus pays $120M in certain scenarios.","Globus board expanded to 11 members; 3 NuVasive directors to be appointed post-close.","David & Sonali Paul (70% voting power) agree to vote Globus Class B shares in favor of issuance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313414,"accession_number":"0001193125-23-029211","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2023-02-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Globus Medical to acquire NuVasive in $3.1B all-stock merger; 0.75 exchange ratio","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Exchange ratio: 0.75 GMED shares per NUVA share; implied price $57.72; equity value $3.1B.","Combined ownership: GMED shareholders 72%, NUVA shareholders 28% on fully diluted basis.","Expects mid-30% EBITDA margin in 3 years and ~$170M in identified cost synergies.","Dan Scavilla to remain CEO; Chris Barry to support integration; board expands to 11 (3 from NuVasive).","Transaction expected to close mid-2023, subject to shareholder and regulatory approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331927,"accession_number":"0001562762-22-000444","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical Q3 net sales $254.1M (+10.6% YoY); lowers FY22 non-GAAP EPS guidance to $2.03","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net sales $254.1M, up 10.6% as-reported and 12.6% constant currency; GAAP net income $47.4M, +0.5% YoY.","GAAP diluted EPS $0.47, non-GAAP diluted EPS $0.50; non-GAAP adjusted EBITDA $82.8M (32.6% of sales).","U.S. Spine sales +9.0%, International Spine +11.1% as-reported (+24.8% constant currency); Enabling Technologies +19.0% to $24.1M.","FY 2022 net sales reaffirmed at $1.025B; non-GAAP diluted EPS guidance lowered to $2.03 from $2.10 due to currency and tax.","Company remains debt-free; operating cash flow $32.9M and free cash flow $20.9M in Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":1.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":748345000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349388,"accession_number":"0001562762-22-000339","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical Q2 net sales $263.6M (+5% YoY); GAAP EPS $0.53, non-GAAP $0.56; Enabling Tech +41.7%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $263.6M, +5.0% as-reported and +6.5% constant currency vs Q2 2021.","GAAP net income $54.6M (+31.4% YoY); diluted EPS $0.53 vs $0.40.","Non-GAAP diluted EPS $0.56; adjusted EBITDA $91.9M (34.9% of sales).","Enabling Technologies sales $29.4M (+41.7%) driven by robotics and Excelsius 3D.","Reaffirmed FY2022 guidance: net sales $1.025B, non-GAAP diluted EPS $2.10."],"consensus_eps_estimate":null,"consensus_eps_actual":0.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":494197000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366308,"accession_number":"0001562762-22-000267","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2022-06-03T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Globus Medical stockholders approve 2021 Equity Incentive Plan amendment at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["At June 2, 2022 annual meeting, stockholders voted to approve amendment to the 2021 Equity Incentive Plan, effective immediately.","Directors David C. Paul, Daniel T. Lemaitre, and Ann D. Rhoads elected to three-year terms with strong stockholder support.","Deloitte & Touche LLP ratified as independent registered public accounting firm for fiscal 2022 (295,235,366 for).","Non-binding advisory vote on named executive officer compensation approved (283,414,921 for).","Plan amendment details (including share reserves, vesting, and award types) incorporated by reference from proxy statement filed April 21, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366307,"accession_number":"0001562762-22-000242","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical Q1 2022 net sales $230.5M, up 1.4% YoY; GAAP EPS $0.37, non-GAAP $0.42","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $230.5M, up 1.4% YoY (1.9% constant currency); U.S. spine sales recovered in March.","GAAP net income $38.1M (-16% YoY); GAAP diluted EPS $0.37 vs $0.44 in Q1 2021.","Non-GAAP diluted EPS $0.42 vs $0.49 in Q1 2021, down 13.1% on higher product development and sales costs.","FY 2022 guidance reaffirmed: net sales $1.025B, non-GAAP diluted EPS $2.10.","First Excelsius3D imaging units shipped; Enabling Technologies pipeline strong."],"consensus_eps_estimate":null,"consensus_eps_actual":0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":230549000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366306,"accession_number":"0001562762-22-000187","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2022-04-21T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Globus Medical names Dan Scavilla as CEO replacing Demski; prelim Q1 sales $230.5M +1.4% YoY","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Demski resigned as CEO effective April 21, 2022; not due to any disagreement; will assist transition through June 30.","Daniel T. Scavilla appointed President & CEO; previously EVP Chief Commercial Officer and President of Trauma.","Preliminary Q1 2022 sales approx. $230.5M, up 1.4% vs Q1 2021; full-year 2022 guidance reaffirmed: $1.025B sales, non-GAAP EPS $2.10.","Scavilla's base salary increased to $450K; target annual non-equity incentive to $900K; receives option for 60,000 shares vesting 4 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385803,"accession_number":"0001562762-22-000117","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2022-03-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Globus Medical expands share repurchase program by $200M; total capacity over $295M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized additional $200M for share repurchases, supplementing ~$95.3M remaining from prior program.","Total available repurchase capacity now exceeds $295M; program has no time limit.","Management retains discretion on timing and amount, based on market conditions and legal requirements.","Funding from cash reserves; company balances capital allocation between growth investments and shareholder returns.","Executive Chairman David Paul cited confidence in long-term growth and earnings strength."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385802,"accession_number":"0001562762-22-000036","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2022-02-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical Q4 sales $250M (+7.1% YoY); FY21 sales $958.1M (+21.4%); guides FY22 sales $1.025B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP diluted EPS $0.14, non-GAAP $0.49; GAAP net income $15.1M down 71.5% due to IPR&D acquisition","Full-year GAAP EPS $1.44, non-GAAP EPS $2.04; adjusted EBITDA $331.4M (34.6% of sales)","Enabling Technology revenue Q4 $25M, FY $81M (+100% YoY); US Spine +18%, International +12%","FY 2022 guidance: net sales $1.025B, non-GAAP diluted EPS $2.10; company remains debt-free","Free cash flow for FY 2021 was $219.4M"],"consensus_eps_estimate":null,"consensus_eps_actual":1.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":958102000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":403691,"accession_number":"0001562762-21-000413","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2021-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical Q3 2021 revenue up 6.3% to $229.7M; GAAP EPS $0.45, non-GAAP $0.50; FY guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide net sales $229.7M (+6.3% YoY); US sales +8.8%, International -7.2%.","GAAP net income $47.2M (20.6% of sales); GAAP diluted EPS $0.45 vs $0.44; non-GAAP diluted EPS $0.50 vs $0.49.","Non-GAAP adjusted EBITDA $78.3M (34.1% of sales); operating cash flow $77.3M; free cash flow $59.5M.","Cash, equivalents and marketable securities $985M; debt-free. FY2021 guidance reaffirmed: net sales $950M, non-GAAP diluted EPS $2.00.","CEO cites market share gains, Enabling Technology momentum, best recruiting quarter, and FDA clearances for Excelsius3D and ExcelsiusHUB."],"consensus_eps_estimate":null,"consensus_eps_actual":1.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":708081000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":422652,"accession_number":"0001562762-21-000296","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2021-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical Q2 revenue $251M (+68.6% YoY); raises FY2021 guidance to $950M sales, $1.89-2.00 EPS","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 worldwide net sales of $251.0M, up 68.6% YoY; GAAP net income $41.5M (16.6% of sales), up 299.4% YoY.","GAAP diluted EPS $0.40, Non-GAAP diluted EPS $0.56, compared to ($0.21) and $0.07 in Q2 2020 respectively.","U.S. Spine business grew ~64% YoY; Enabling Technologies revenue $21M (nearly 4x Q2 2020).","Raised FY2021 guidance: net sales to $950M (from $925M) and non-GAAP diluted EPS to $1.89-$2.00.","Cash and marketable securities $914.2M, no debt; generated $59.2M operating cash flow, $50.8M free cash flow in Q2."],"consensus_eps_estimate":null,"consensus_eps_actual":0.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":478360000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}